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Abstract
Tumor hypoxia is relevant for tumor growth, metabolism and epithelial-to-mesenchymal transition (EMT). We report that
hyperbaric oxygen (HBO) treatment induced mesenchymal-to-epithelial transition (MET) in a dimetyl-a-benzantracene
induced mammary rat adenocarcinoma model, and the MET was associated with extensive coordinated gene expression
changes and less aggressive tumors. One group of tumor bearing rats was exposed to HBO (2 bar, pO2 = 2 bar, 4 exposures a`
90 minutes), whereas the control group was housed under normal atmosphere (1 bar, pO2 = 0.2 bar). Treatment effects were
determined by assessment of tumor growth, tumor vascularisation, tumor cell proliferation, cell death, collagen fibrils and
gene expression profile. Tumor growth was significantly reduced (,16%) after HBO treatment compared to day 1 levels,
whereas control tumors increased almost 100% in volume. Significant decreases in tumor cell proliferation, tumor blood
vessels and collagen fibrils, together with an increase in cell death, are consistent with tumor growth reduction and tumor
stroma influence after hyperoxic treatment. Gene expression profiling showed that HBO induced MET. In conclusion,
hyperoxia induced MET with coordinated expression of gene modules involved in cell junctions and attachments together
with a shift towards non-tumorigenic metabolism. This leads to more differentiated and less aggressive tumors, and
indicates that oxygen per se might be an important factor in the ‘‘switches’’ of EMT and MET in vivo. HBO treatment also
attenuated tumor growth and changed tumor stroma, by targeting the vascular system, having anti-proliferative and pro-
apoptotic effects.
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Introduction
Hypoxia is a common feature in tumors and studies have
demonstrated that it promotes aggressive tumor behavior, invasive-
ness and metastatic potential [1,2]. The disorganized and
dysfunctional tumor vasculature is generally attributed to this
deficiency in oxygen supply. As hypoxia represents a hallmark of
solid tumor growth and metastasis, we aimed to study the effect of
enhanced oxygenation (‘‘the flip of the coin’’), by using hyperbaric
oxygen (HBO) treatment in a rat tumor model. When oxygen is in
solution, it can more easily reach tissue areas where blood cells
cannot pass, and can also enable tissue oxygenation even with
impaired haemoglobin carriage [3]. As in normal tissue, the oxygen
partial pressure (pO2) in tumor tissue increases significantly during
HBO exposure [4] and the pO2 elevation lasts for up to 60 min post
HBO treatment [5]. This type of therapy is frequently used to treat a
number of diseases including carbon monoxide poisoning and non-
healing wounds [6]. Furthermore, HBO co-treatment has been used
extensively and successfully to potentiate therapeutic effects of
chemotherapy and radiotherapy, both clinically and in animal
models [7]. Recent studies have also concluded that HBO has a
significant inhibitory effect per se on the growth of mammary tumors
[8,9] and BT4C glioma xenografts in rats [10].
Various cellular functions are influenced by the availability of
oxygen, via different molecular sensor-systems regulating signal-
ling, metabolism and gene-expression. The transcriptional com-
plex Hypoxia inducible factor-1 (HIF-1) is a major oxygen
sensitive regulator [11]. HIF-1 is regulated through hydroxylation,
poly-ubiquitylation and proteasomal degradation of the HIF-1a
subunit under normoxic conditions. Under hypoxic conditions
HIF-1a is stabilised, and this results in the transcriptional
induction of hypoxia-responsive genes encoding proteins that will
promote O2 delivery (VEGF, erythropoietin) and mediate
metabolic adaption to reduced O2 availability (glucose transport-
er-1, glycolytic enzymes) [12]. Through this signalling-pathway,
enhanced pO2 during and after HBO may influence gene
expression and cellular responses, also in tumors.
In recent years, several investigations have suggested that the
process of epithelial–to-mesenchymal transition (EMT) may be
crucial for carcinogenesis and cancer progression [13,14,15,16,17].
Cannito et.al. [18] provided evidence that tumors exposed to
moderate hypoxic conditions can trigger a highly conserved cellular
program. EMT is a fundamental process that governs morphogen-
esis in multicellular organisms [16]. In tumor progression, EMT is
involved in a dedifferentiation program that leads to malignant
carcinomas with an invasive or metastatic phenotype [15,16,19].
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Cell morphology, adhesion to other cells and the extracellular
matrix (ECM), and migration potential are all features that change
during this transition. Loss of E-cadherin (CDH1) expression is one
of the hallmarks of EMT, as CDH1 expression is one of the
important features of the epithelial phenotype. CDH1 is a cell-cell
adhesion molecule that participates in homotypic, calcium-
dependent interactions to form epithelial adherens junctions.
Several transcription factors have been associated with the
repression of CDH1, including zinc finger proteins of the SNAIL
and TWIST families, dEF1/ZEB1/TCF8, SIP1/ZEB2/ZFHX1B
and the basic helix-loop-helix factor E12/E47 [15]. Loss of CDH1
is also associated with a gain of N-cadherin (CDH2), in a process
known as the ‘‘cadherin switch’’. CDH2 enhances tumor cell
motility and migration and has been postulated to exert a dominant
effect over CDH1 function. CDH2-dependent motility may be
mediated by fibroblast growth factor receptor (FGF-receptor)
signalling [20,21] and this process is potentially implicated in EMT.
Oxygen is a prerequisite for mitochondrial respiration, and an
important regulator of energetic pathways. Normal cells utilize
glycolysis and mitochondrial oxidative phosphorylation as the two
major ATP generating pathways under normoxic conditions. For
example in muscle, glycolysis is stimulated under conditions when
insufficient oxygen supply limits oxidative phosphorylation, which
consequently leads to increased lactate production. Most solid tumors
develop a metabolic phenotype that includes high rates of glycolysis
and lactate production, even under normoxic conditions [22]. The
presence of such ‘‘aerobic glycolysis’’, combined with low rates of
mitochondrial respiration, is now recognized as a general feature of
solid tumors (the Warburg effect), and tumor energy metabolism is
therefore regarded as a promising therapeutic target [23].
Thus, the aim of the present study was to elucidate the effect of
4 treatments of 2 bar pure oxygen on tumor growth and on factors
that influence tumor growth such as angiogenesis, cell death,
proliferation, collagen density and metabolism. In addition, we
aimed to investigate the influence of hyperoxia on the gene
expression profile. The results indicate that oxygen by itself can
induce MET in an in vivo cancer model.
Materials and Methods
Animals and tumor model
A total of 40 female Sprague-Dawley rats (Møllega˚rd, Denmark)
were used. Mammary tumors (adenocarcinomas) were induced by
dimetyl-a-benzantracene (DMBA) dissolved in olive oil and given to
the rat by gavage at the age of 7 weeks at a dose of 16 mg. The
experiments were performed when the rats were 13–15 weeks old,
having reached a bodyweight of approximately 250 g and developed
one to three tumors along the mammary crest. All the experiments
were performed in accordance with recommendations of the
Norwegian State Commission for Laboratory Animals and experi-
mental procedures were approved by the local ethical committee.
Hyperbaric chamber
A 30 l pressure chamber (Skjønndal Slipp, Bergen, Norway)
with an inner diameter of 25 cm, and an inner length of 65 cm
was used. The chamber was supplied with pure O2, and the
percent of oxygen was monitored continuously by an oxygen
meter (NUI, Bergen, Norway). After reaching 100% O2 within
approximately 10 min, the pressure was raised over a period of
approximately 3 min to 2 bar. The 2 bar pure oxygen atmosphere
was maintained for a period of 90 min. To maintain.97% O2
atmosphere at all times, the chamber was flushed with pure
oxygen for 3–5 min every 10–30 min depending on the number of
animals in the chamber.
Experimental groups and treatment design
The HBO treated rats were exposed to 2 bar pure oxygen for
90 min at day 1, 4, 7 and 10, and rats were killed day 11. The
controls were exposed to normal atmospheric pressure and air for
an equal period of time.
Measurements of tumor growth
Tumor size was measured externally with a caliper at day 1 (pre
hyperoxic exposure) and day 11 (post hyperoxic exposure) and
estimated according to the formula: p/6 ?(a2)?(b), where a is the
shortest and b is the longest transversal diameter [24]. The rats
were anesthetized by isoflurane (Rhone-Poulenc Chemicals,
France) and N2O and body-temperature was kept at 3760.5uC.
Immunohistochemistry
The animals were sacrificed with saturated KCl during
anaesthesia and the tumors were immediately dissected out and
put into liquid N2 and then stored at 280uC or fixed in 4%
formalin, processed and embedded in paraffin until use.
Frozen tumor sections (20 mm) were used for immunostaining of
blood vessels using mouse anti-rat CD31 (Serotec, MCA 1334G,
Du¨sseldorf, Germany) as primary antibody and biotinylated rabbit
anti-mouse (DAKO, no E0413, Oslo, Norway) as secondary
antibody. Diaminobenzidine (DAB) was used as a chromogen to
visualize blood vessels, and hematoxylin (H & E, Merck, Damstadt,
Germany) was used a nuclear counterstain. The cross-sectional
density of CD31 positive structures was quantified per mm2 using a
counter grid, while the blood vessel diameter was measured on
longitudinal structures in ‘‘hotspot’’ areas from 10 (406) high power
fields (HPF) for each tumor. Staining for CDH2 was performed on
frozen sections of tumor tissue using the monoclonal mouse CDH2
antibody M3613 (DAKO, Copenhagen, Denmark) diluted 1:25 and
incubated for 1 hr at room temperature. Staining for CDH1 was
performed on frozen sections of tumor tissue using the rabbit
polyclonal antibody Ab53226 (Abcam, Cambridge, UK) diluted
1:50 and incubated for 2 hrs at room temperature. Staining was
done using the EnVision-labeled polymer method, with commercial
kits (DAKO). The antigens were localized by the diaminobenzidine
tetrachloride peroxidase reaction, and the slides were counter-
stained with Mayer’s hematoxylin.
Paraffin embedded tumor sections (10 mm) were used for
proliferation and apoptosis staining. Tumor cell proliferation was
assessed by staining with an anti-rat Ki67 monoclonal antibody
diluted 1:15 (No. M7248, Dako Cytomation, Denmark), and
secondary antibody from DAKO envision kit (DACO Patts,
Glostrup, Denmark). Cell death was examined by the terminal
transferase-mediated dUTP nick-end-labeling (TUNEL) method
(Boehringer Mannheim, Mannheim, Germany), performed accord-
ing to the manufacturers recommendation, as described in reference
[10]. Tumor proliferation was quantified as the percent of Ki67
positive cells per visionfield. All sections were examined using a
Nikon light microscope (THP Eclipse E600, Nikon Corporation,
Tokyo, Japan) and the images were captured with a Nikon Digital
Camera (DXM 1200F, Nikon Corporation, Tokyo, Japan).
Determination of collagen content in the tumors
Transmission electron microscopy (TEM) was used to examine
tumor collagen fibrils. The tumor pieces were fixed in 2.5%
glutaraldehyde in 0.2M (CH3)2 As( = o)ONa and stained with
osmium using standard procedures. The pieces were then
moulded into Agar 100 Resin plastic and sliced into 60 nm thick
sections, before they were marked with lead-citrate and uranyl-
acetate and analysed in a transmission electron microscope (JEM-
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1230, Jeol, Japan). The number of collagen fibrils on represen-
tative cross-sectional pictures each of 29 mm2 from both control
and repeated HBO treated tumors were counted, and the average
number of fibrils per mm2 were calculated.
Global Gene Expression Analysis
Global gene expression analysis was performed, studying changes in
gene clusters, in order to identify key molecular mechanisms and
changes in gene programs. Changes in gene-expression profiles after
HBO suggested several relevant pathways to be involved. A total of 6
controls and 4 HBO treated tumors were analysed. The Agilent
G413F Whole Rat Genome (4644k) Oligo Microarray Kit with
SurePrint Technology (Agilent Technologies, Inc., Palo Alto, CA) was
used to analyze samples in the present study. One mg of DNAse-
treated total RNA was converted into cDNA and Cy3-labeled cRNA
using the Low RNA Input Linear Amplification Kit PLUS, One-
Color kit (Agilent Tech., Santa Clara, CA, USA) as previously
described [17]. The normalized channel values were log(2) trans-
formed and combined into a gene expression data matrix. Data were
formatted in a J-Express-file suitable for additional data mining
(http://www.molmine.com/) [25]. Following normalization, the
tumor samples were divided in two groups, the HBO treated and
non-treated tumors. We used analysis of variance (ANOVA), t-score
analysis and SAM (Significant Analysis of Microarray) of the J-Express
program package for identification of differentially expressed genes.
Annotated microarray data were uploaded in the BASE database and
formatted and exported to ArrayExpress at the European Bioinfor-
matics Institute (http://www.ebi.ac.uk/microarray/) in agreement
with the MIAME guidelines (E-TABM-718).
Statistics
Unpaired t-test was used to compare results between the groups
(angiogenesis, proliferation, apoptosis, and tumor growth). Paired
t-test was used when comparing results within the same group of
animals. A value of p,0.05 was considered statistically significant.
SigmaPlot 8.0 (Alfasoft AS, Lillestrøm, Norway) was used for the
statistical evaluation.
Results
Tumor volume
A total of 20 controls and 20 HBO treated tumors were measured.
The measurements of tumor volume started approximately 5 weeks
post DMBA induction, when the tumors were approximately 1.0–
2.5 cm3. During the observation period of 11 days, tumor volume
increased significantly in controls (p,0.0001), whereas a marked
reduction in tumor volume (p,0.0001) was found in HBO treated
tumors compared to pre-treatment sizes at day 1 (Fig. 1A).
Hyperoxia changes tumor morphology and cadherin
expression
DMBA-induced mammary control tumors showed mostly
undifferentiated growth with high cellularity and marked nuclear
pleomorphism (n = 6) (Fig. 1B). However, after HBO treatment a
majority of the cases appeared to have a more differentiated
morphology, with glandular structures and less marked cellular
atypia as well as areas of cell death (n = 5) (Fig. 1C). Expression of
CDH2 protein was weaker in the HBO treated, differentiated
tumors and was found to be clearly increased in the less
differentiated control tumors, whereas the opposite was found
for CDH1 expression (Fig. 2). In positive cases, staining was
uniform with distinct protein expression in a majority of the tumor
cells.
Hyperoxia changes tumor vascular density and diameter
To determine the impact of hyperoxia on the tumor vasculature,
the vascular density in ‘‘hot spot’’ areas both in the tumor centre and
periphery, was examined. The number of CD31 positive tumor
blood vessels per mm2 were significantly reduced (,40%) after HBO
treatment (n = 5 for both groups), as shown in Table 1. The tumor
vessel diameter was also changed after HBO. A reduction in vessel
diameter was found in the periphery of the tumor, while centrally the
vessels were dilated (Table 1). Microarray analysis confirms the anti-
angiogenic effect of HBO on DMBA-induced tumors, with reduced
levels of growth factors like Vegf, Fgf and Tgf (Table 2).
Hyperoxia reduces tumor cell proliferation
The effect of hyperoxia on tumor growth may be due to a
reduction in tumor cell proliferation. We therefore immunostained
the tumors for the cell proliferation marker Ki67, and interest-
ingly, the proportion of Ki67 positive tumor cells were less in the
HBO exposed group (n = 5 for both groups). Thus, hyperoxia
induces a significant reduction in proliferating tumor cells
(Table 1). Gene expression profile analysis confirms the regulation
of tumor growth factors (Table 2).
Figure 1. Tumor growth and morphology. Tumor growth (% of initial volume) in control and hyperbaric oxygen (HBO) treated tumors after 11
days (A). Box plot presented as means 6 SEM. ** p,0.001 compared to controls. DMBA-induced mammary control tumors showed mostly poorly
differentiated growth with high cellularity and marked nuclear pleomorphism (B). After HBO treatment, a majority of the cases appeared to have a
more differentiated morphology, with glandular structures and less marked cellular atypia and showed large areas of cell death (C).
doi:10.1371/journal.pone.0006381.g001
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Hyperoxia enhances cell death
To determine whether the reduction in tumor growth was
related to induction of cell death, we performed TUNEL staining,
and counted the TUNEL labeled cells in the tumors (n = 5 for both
groups). As shown in Table 1, the number of dead cells in the
tumor was significantly increased (p,0.001) after HBO treatment.
Genes related to apoptosis are elucidated in Table 2, confirming
the immunohistochemical finding.
Hyperoxia influences fibrosis
There were pronounced differences in collagen fibril density in
tumor stroma between control (n = 5) and HBO treated (n = 4)
tumors, as displayed in Figures 3A and B. The manually counted
fibril density showed a statistically significant decline in fibril
density after HBO treatment (Fig. 3C) (p,0.001). The results are
supported by microarray analysis, showing down-regulation of
several fibrosis-related genes (Table 2).
Hyperoxia induces mesenchymal-to-epithelial transition
Whole genome gene expression profiling was used to investigate
if hyperoxia could influence EMT in an in vivo tumor model.
Table 3 presents expression values of epithelial and mesenchymal
cell markers in HBO treated tumors compared to untreated
control tumors. The results show a significant shift from
mesenchymal to epithelial cell marker expression. A significant
up-regulation of most of the genes involved in maintenance of the
epithelial phenotype, like Cdh1, and a significant down-regulation
of Cdh2, a marker of the mesenchymal phenotype, was found. Cdh1
inhibitors such as Snai1 and Twist2 were significantly down-
regulated in the HBO treated tumors compared to control, and
could promote the mesenchymal-to-epithelial transition. Further-
more, gene expression of entire cell junction and attachment
modules such as adherens junctions, gap junctions, tight junctions,
desmosomes and hemidesmosomes were coordinately and strongly
induced in the HBO treated rats (Supplementary Table S1).
Figure 2. Cadherin expression (CDH1 and CDH2). Expression of CDH2 protein (N-cadherin) by immunohistochemistry was weaker in the HBO
treated, differentiated tumors (B) and was found to be clearly increased in the less differentiated control tumors (A), whereas the opposite was found
for CDH1 (E-cadherin) expression (C and D;6400).
doi:10.1371/journal.pone.0006381.g002
Table 1. Proliferation, blood vessel density and apoptosis in
controls and after hyperbaric oxygen exposure (HBO). (Mean
values 6 SEM).
Control HBO
Blood vessel density (numbers/mm2)
Centrally 43.667.7 17.467.9**
Periferally 39.265.7 15.766.0***
Blood vessel diameter (mm2)
Centrally 5763.2 77.367.2***
Periferally 58.963.4 30.362.6***
Proliferation (% Ki67 positive tumor cells) 1962.9 961.0 **
Apoptosis (% of total area) 8.663.3 34.765.6***
**p,0.02 vs control.
***p,0.001 vs control.
doi:10.1371/journal.pone.0006381.t001
Hyperoxia Induces MET In Vivo
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Selected gene expressions were validated by immunohistochemical
staining (Fig. 2).
Hyperoxia induces a metabolic shift
There were strong indications that the tumor energy metabolism
was shifted away from aerobic glycolysis after HBO treatment
(Table 2). The glycolytic enzymes hexokinase II and glyceraldehyde
3-phosphate dehydrogenase (Gapdh) were significantly reduced after
HBO treatment, opposing the tumor specific metabolic glycolytic
phenotype. Furthermore, the lactate dehydrogenase (Ldh) expression
profile was also changed. Our data showed a significant reduction in
Ldha expression together with a dramatic increase in Ldhb expression.
The relative changes in Ldha and Ldhb expression strongly suggest the
formation of Ldh isoforms with a preference for catalysis in the lactate-
pyruvate direction.
Discussion
The present study showed a significant reduction (,16%) in
DMBA-induced mammary tumor size after 2 bar HBO treatment
compared to day 1. This corresponds to the reduction found by
Stuhr et al. [9] on an identical tumor model and after identical
Table 2. Markers of apoptosis, tumor growth, fibrosis and metabolism in HBO treated mammary adenocarcinoma.
Genes Gene name Expression p-values
Apoptosis facilitators
Perp TP53 apoptosis effector 60 5.2E-21
Bik Bcl2-interacting killer 5.7 5.1E-08
Casp6 Caspase 6 4.1 1.3E-05
Bbc3 PUMA 2.0 4.1E-05
Bak1 BCL2-antagonist/killer 1 2.0 2.1E-05
Bid3 BH3 interacting domain death agonist 1.5 1.3E-02
Bax Bcl-associated X protein (apoptosis-inducing) 1.5 7.2E-04
Bnip3l BCL2/adenovirus E1B 19 kDa-interacting protein 3 1.3 3.0E-04
Apoptosis inhibitors
Bcl2l2 Bcl2-like2 1.8 1.7E-7
Bcl2 Bcl-2 beta protein 1.3 4.1E-3
Birc3 Baculoviral IAP repeat-containing 3 0.8 2.6E-3
Ciapin1 Cytokine induced apoptosis inhibitor1 0.7 2.1E-3
Becn1 Autophagy related Beclin 1 0.7 3.6E-4
Bag1 Bcl2-associated athanogene 1 0.7 9.9E-4
Tmbim1 BAX inhibitor motif containing1 0.3 2.1E-4
Birc5 Survivin 0.2 1.1E-4
Nol3 Apoptosis repressor with CARD domain 0.2 2.1E-10
Birc2 Baculoviral IAP repeat-containing 2 0.1 4.4E-14
Tumor growth factors
Vegfa Vascular endothelial growth factor A 0.1 9.8E-9
Vegfb Vascular endothelial growth factor B 0.3 1.7E-7
Fgfr1 Fibroblast growth factor receptor 1 0.2 1.1E-7
Tgfa´ Transforming growth factor, alpha 0.3 4.1E-7
Tgfb1 Transforming growth factor, beta 1 0.6 1.9E-4
Tgfb2 Transforming growth factor, beta 2 0.3 2.3E-5
Tgfbr1 Transforming growth factor, beta receptor 1 0.6 1.3E-4
Tgfbr2 Transforming growth factor, beta receptor 2 0.3 2.5E-7
Fibrosis
Agc1 Aggrecan 1 0.5 4.1E-4
Lum Lumican 0.5 8.8E-3
Fmod Fibromodulin 0.2 1.5E-3
Metabolism
Ldhb Lactate dehydrogenase B 10 1.0E-5
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 0.5 1.3E-4
Ldha Lactate dehydrogenase A 0.4 1.3E-8
Hk2 Hexokinase II 0.2 1.6E-7
Displayed results are fold change of gene expression in HBO treated rat mammary adenocarcinomas compared to untreated tumors.
doi:10.1371/journal.pone.0006381.t002
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treatment. Raa et al. [8] also showed reduction of DMBA-induced
tumor growth after normobaric (1 bar) and hyperbaric (1.5 bar)
hyperoxia (100% O2), although not to the same extent. Taken
together, the results indicate that the reduction in DMBA-induced
tumor growth is dose-dependent on pO2.
Angiogenesis is essential for tumor growth and has been shown
to be hypoxia-induced. One might therefore expect that
hyperoxia may inhibit the angiogenic switch. However, hyper-
oxia is known to increase vessel development in normal tissue and
in wound healing [26]. Interestingly, we found a significant
reduction in mean vascular density after HBO treatment in the
present mammary tumors. This indicates that hyperoxia has an
anti-angiogenic effect on these tumors. This anti-angiogenic
effect applies both for the central and peripheral parts of the
tumor. The gene expression analysis supports this, and shows a
significant down-regulation of pro-angiogenic genes such as
Vegfa, Vegfb, Fgf, Pdgf and Tgfa after HBO treatment (Table 2). As
blood vessels are necessary to nurture the tumor tissue, this anti-
angiogenic effect could help explain the restriction in tumor
growth. A similar anti-angiogenic effect was found previously in
transplanted gliomas after 2 bar pure oxygen treatment [10].
Thus, hyperoxia could potentially be used for anti-angiogenic
therapy in tumors.
The mean vascular diameter is also changed after treatment.
Peripherally, the vessels are constricted, the same reaction as in
normal blood vessels when treated with HBO. In contrast, vessels
in the central parts of the tumors are dilated. Raa et.al. [8]
identified the same dilatory effect in DMBA induced tumors
treated with normobaric and hyperbaric (1.5 bar) hyperoxia. We
might therefore speculate that this dilation is the tumor’s response
to elevate its flow, and thereby compensate for loss of blood vessels.
HBO also significantly decreased tumor cell proliferation. This is
a direct inhibition of dividing cells, and thereby of tumor growth. A
study by Granowitz et.al. [27] corresponds to our results by showing
that HBO inhibited both benign and malignant human mammary
epithelial cell proliferation in vitro. They also showed that the anti-
proliferative effect of HBO alone was similar in magnitude to the
effect of high-dose of melphala, gemcitabine and paclitaxel alone,
indicating that HBO could be an effective therapy for breast cancer.
A significant increase in cell death after repeated HBO can also
help explain the tumor inhibitory effect. Several factors in the
apoptotic machinery are influenced by HBO treatment. The
induction of apoptosis by p53 is fundamental and the targets
PUMA, BAX, BAK, BIK and PERP play cell type-specific roles in
p53-mediated apoptosis. Gene expression analysis shows a strong
induction of Perp, an apoptotic effector that promotes mitochon-
drial membrane permeability and is involved in cell adhesion and
cell junction as well [28,29]. The striking picture of increased
apoptotic facilitators and down-regulation of apoptotic inhibitors
(Table 2) supports the observation of elevated number of TUNEL
positive tumor cells after HBO treatment. This also corresponds
with previous findings in DMBA-induced mammary tumors after
1 and 1.5 bar HBO treatment [8] and in transplanted gliomas in
nude rats after both 1 and 2 bar HBO treatment [10].
Figure 3: Collagen density. The collagen fibril density is shown in control (A) and hyperbaric oxygen (HBO) treated tumors (B) on cross-section
fibrils magnified 50.000 times. Scale bar indicates 0.5 mm. Manually counted collagen fibril density 6 SEM (C). **p,0.001 compared to controls.
doi:10.1371/journal.pone.0006381.g003
Table 3. Mesenchymal-to-epithelial transition markers in HBO
treated mammary adenocarcinoma.
Genes Expression p-values
Epithelial markers
Areg 280 1.6E-11
Krt14 173 1.5E-12
Krt5 138 8.7E-14
Cdh1 88 1.9E-6
Perp 60 5.2E-21
Dsp 25 8.4E-14
Serpinb 10 1.2E-5
Ocln 7 6.0E-10
Cdh3 1.3 2.8E-3
Mesenchymal markers
Snai1 0.11 2.2E-10
Fgfr1 0.17 1.1E-7
Cdh2 0.19 4.9E-7
Fn1 0.27 5.6E-6
Cdh11 0.27 2.1E-3
S100a4 0.28 2.2E-11
Bmp7 0.28 4.4E-5
Fzd2 0.34 2.8E-4
Twist2 0.44 3.4E-4
Nid1 0.58 2.5E-3
Vim 0.67 5.0E-3
Displayed results are fold change of gene expression in HBO treated mammary
adenocarcinomas compared to untreated tumors detected by use of Agilent
Human Whole Genome Oligo Microarrays and SAM software analysis. The p-
values are based upon t-score analysis and SAM and FDR less than 1%.
doi:10.1371/journal.pone.0006381.t003
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Several reports have previously suggested that EMT is crucial
for cancer progression [15,16]. This process converts adherent
epithelial cells to mobile mesenchymal appearing cells. Cell-
junctions, especially adherens junctions, tight junctions and
desmosomes, are required for the epithelial phenotype and for
epithelial cells to function as a tissue [30]. A strong induction of
genes associated with these cellular junctions was found after HBO
treatment indicating a transition towards an epithelial phenotype
(Table 3; Supplementary Table S1). The functional loss of CDH1,
is a key event in the EMT process [13]. Cowin et.al. [20] provided
evidence that CDH1 serves both as a tumor suppressor and an
invasion suppressor in an animal model of invasive lobular breast
cancer (ILC). Several transcription repressors, such as SNAI1,
SNAI2 and TWIST have been identified as strong repressors of
CDH1 [31,32]. Our gene expression analysis on DMBA-induced
mammary tumors showed that mesenchymal cell markers are
significantly down-regulated in 2 bar HBO treated tumors
compared to controls. The results show a significant up-regulation
of Cdh1, concomitant with a down-regulation of Snai1 and Twist2
among others (Table 3, Fig. 2). Reexpression of Cdh1 might
counteract migration and metastasis of cancer cells [20].
Reduction of CDH1 is often accompanied by reciprocally
increased expression of CDH2 [21], and indeed CDH2 has been
shown to promote breast cancer cell invasiveness in various studies
[21,33]. CDH2 is a well regarded marker of EMT and we found a
significant down-regulation of cdh2 (Table 3, Fig. 2), thus
confirming MET [19]. The TGFb family of cytokines has been
shown to promote EMT during cancer progression [31,34,35] and
this is in accordance with the present study showing a strong
down-regulation of Tgfb1, Tgfb2 and the receptors Tgfbr1 and 2
(Table 2) after HBO treatment. Furthermore, the hedgehog signal
pathway is known to promote EMT and cell migration. In the
HBO treated adenocarcinomas the many components of the
hedgehog pathway were significantly suppressed (data not shown).
Thus, the restoration of a MET programme should efficiently slow
the dedifferentiation and dissemination of tumor cells, and thereby
result in a less aggressive tumor phenotype [16,36] as we see in
Figure 1C. The present study implicates oxygen per se as a
significant mediator of the MET ‘‘switch’’. To the best of our
knowledge, this is the first study to discover that oxygen per se
might be a significant contributor to mesenchymal-to-epithelial
transition in vivo.
EMT has also shown an important role in fibrosis of lungs, liver,
kidney and cancer, and TGF-b is a key mediator of EMT in fibrosis
[13,37]. Tumor stroma is characterized by activated connective
tissue cells producing a collagen-rich matrix. It is therefore very
interesting that the HBO treated tumors had a reduction in Tgfb
(Table 2) and also a concomitant reduction in the number of
collagen fibrils (Fig. 3). Additionally, Oldberg et.al. [38] described
the effect of the small leucine-rich repeat proteoglycan (SLRP),
fibromodulin, in collagen assembly and maintenance, producing a
dense stroma. They showed that fibromodulin deficiency resulted in
altered tissue organization with fewer and abnormal collagen fibril
bundles. In accordance with the reduction in fibrosis, our analysis
showed a significant down-regulation of fibromodulin in the HBO
treated tumors. Additionally, two other fibrosis-related genes,
aggrecan1 (Agc1) and lumican (Lum) are down-regulated in the
HBO treated tumors (Table 2). This indicates that hyperoxic
induced MET and has an anti-fibrotic effect as well in the present
mammary adenocarcinomas.
The energy metabolism in tumors is highly glycolytic, inducing
excessive lactate secretion and acidification of the tumor
environment which facilitates tumor invasion. Therefore, targeting
the energy metabolism has been proposed to represent a possible
therapeutic strategy in the treatment of human cancer [23]. The
first critical step in glycolysis is phosphorylation of glucose, which
is performed by hexokinases. These enzymes participate in glucose
catabolism. The present study shows a clear down-regulation of
hexokinase II after HBO treatment. Interestingly, we also see a
change in the Ldh expression profile after HBO treatment, with
reduced lactate dehydrogenase A (Ldha) and up-regulation of
lactate dehydrogenase B (Ldhb). The relative abundance of the
subunits Ldha and Ldhb seems to determine direction of the
catalytic activity [39]. A higher portion of Ldhb leads to increased
amounts of pyruvate (from lactate), which is a common substrate
for mitochondrial oxidation (Table 2). Taken together these
findings indicate a shift towards non-tumorigenic metabolism, and
thereby a shift towards tumor- suppressing alterations in signal
transduction.
In conclusion, we have shown that hyperoxia induces a
coordinated alteration of entire gene modules of cell junctions
and attachments and a MET. This leads to more differentiated
and less aggressive DMBA-induced mammary tumors, and
indicates that oxygen per se might be an important factor in the
‘‘switches’’ of EMT and MET in vivo. HBO treatment also
attenuates tumor growth and changes tumor stroma by targeting
the vascular system, having anti-proliferative and pro-apoptotic
effects. In addition, hyperoxia shifted the metabolism from
glycolysis to oxidative phosphorylation. Thus, as hypoxia acts as
a tumor promoter, hyperoxia acts as a tumor suppressor in DMBA
induced mammary tumors in rats. However, further studies are
needed to elucidate the underlying mechanisms.
Supporting Information
Table S1 Expression of cell junction genes in HBO treated rat
mammary adenocarcinomas compare to control.
Found at: doi:10.1371/journal.pone.0006381.s001 (0.08 MB
DOC)
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